What is Xeljanz?

Xeljanz (tofacitinib) is a medication classified as a Janus kinase (JAK) inhibitor that has revolutionized treatment for several autoimmune conditions. Developed by Pfizer, this oral medication represents an alternative to injectable biologics that many patients with autoimmune disorders previously relied on.

Available in immediate-release tablets, extended-release tablets, and oral solution formulations, Xeljanz has received FDA approval for treating moderate to severe rheumatoid arthritis, active psoriatic arthritis, moderate to severe ulcerative colitis, and active polyarticular course juvenile idiopathic arthritis. The medication works differently from traditional disease-modifying antirheumatic drugs (DMARDs) like methotrexate and biologics like TNF inhibitors, offering a unique mechanism of action.

The Mechanism of Action of Xeljanz

At its core, Xeljanz functions by inhibiting specific enzymes called Janus kinases (JAKs). These enzymes play crucial roles in the signaling pathways that regulate immune responses within your body. When you have an autoimmune condition, these signaling pathways become overactive, causing your immune system to attack healthy tissues.

Specifically, Xeljanz blocks JAK1 and JAK3, two members of the JAK family of enzymes. These enzymes normally help activate signal transducers and activators of transcription (STATs), which then enter the cell nucleus and influence gene expression related to immune function. By inhibiting these JAKs, Xeljanz interrupts the signaling cascade that leads to inflammation and tissue damage in autoimmune diseases.

Unlike biologics that target external signaling proteins like tumor necrosis factor (TNF), Xeljanz works inside cells to disrupt the inflammatory process at an earlier stage. This intracellular mechanism provides a different approach to managing autoimmune conditions, potentially offering benefits for patients who don't respond well to other treatments.

Xeljanz Treatment Comparison

When considering treatment options for autoimmune conditions, it's important to understand how Xeljanz compares to alternatives. Pfizer, the manufacturer of Xeljanz, positions it as an oral alternative to injectable biologics, which may be preferable for patients with needle aversion.

Compared to traditional DMARDs like methotrexate from Teva Pharmaceuticals, Xeljanz typically works more quickly, with some patients reporting improvements within days rather than weeks or months. However, Xeljanz is generally prescribed after a patient has tried and failed other treatments due to its safety profile.

When compared to TNF inhibitors like Humira from AbbVie, Xeljanz offers the convenience of oral administration versus injections. Studies have shown comparable efficacy in conditions like rheumatoid arthritis, though individual responses vary significantly. The choice between these medications often depends on factors like comorbidities, convenience preferences, and insurance coverage.

Other JAK inhibitors on the market include Rinvoq (upadacitinib) from AbbVie and Olumiant (baricitinib) from Eli Lilly. Each has slightly different JAK selectivity profiles, which may influence their efficacy and side effect profiles for specific conditions.

Benefits and Risks of Xeljanz

The primary benefit of Xeljanz is its effectiveness in reducing inflammation and symptoms in several autoimmune conditions. Many patients experience significant improvements in joint pain, swelling, and mobility when taking Xeljanz for rheumatoid or psoriatic arthritis. For those with ulcerative colitis, the medication can help reduce bowel inflammation and associated symptoms.

Another advantage is the oral administration route, eliminating the need for injections that many biologic medications require. This can improve treatment adherence for patients uncomfortable with self-injection. Additionally, Xeljanz doesn't require refrigeration like many biologics do, making it more convenient for travel and storage.

However, Xeljanz carries significant risks that must be carefully considered. The FDA has issued boxed warnings for serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality. Patients taking higher doses of Xeljanz have shown increased risks of blood clots and death compared to those taking TNF blockers, according to safety trials conducted by FDA.

Common side effects include upper respiratory infections, headache, diarrhea, and nasopharyngitis. Regular monitoring through blood tests is necessary to check for changes in lymphocyte counts, neutrophil counts, hemoglobin, and liver enzymes. Patients with a history of diverticulitis, tuberculosis, or hepatitis B or C require special consideration before starting Xeljanz.

Xeljanz Dosing and Administration

Xeljanz dosing varies depending on the condition being treated and patient-specific factors. For rheumatoid arthritis, the standard dose is 5 mg twice daily or 11 mg once daily (extended-release). For ulcerative colitis, an initial higher dose of 10 mg twice daily is often prescribed for induction, followed by a maintenance dose of 5 mg twice daily.

The medication can be taken with or without food, though some patients find taking it with food helps reduce gastrointestinal side effects. It's important to take Xeljanz exactly as prescribed, at the same times each day, to maintain consistent blood levels of the medication.

Before starting Xeljanz, patients should undergo screening for tuberculosis and viral hepatitis. According to American College of Rheumatology guidelines, regular blood monitoring is recommended during treatment to check for potential side effects on blood cells, liver function, and cholesterol levels.

Xeljanz is available through specialty pharmacies with a prescription from a rheumatologist, gastroenterologist, or other specialist. Xeljanz manufacturer Pfizer offers patient assistance programs that may help with affordability for eligible patients, as the medication can be costly without adequate insurance coverage.

Conclusion

Xeljanz represents an important advancement in the treatment of autoimmune conditions through its unique mechanism of targeting JAK enzymes. By interrupting the cellular signaling pathways that drive inflammation, this medication offers relief for many patients with conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. However, the decision to use Xeljanz should involve careful consideration of its benefits against potential serious risks, including infections, blood clots, and cardiovascular events.

Patients considering Xeljanz should work closely with their healthcare providers to determine if this medication is appropriate for their specific situation, taking into account their medical history, risk factors, and previous treatment responses. With proper monitoring and adherence to recommended guidelines from organizations like the American College of Rheumatology, Xeljanz can be an effective component of a comprehensive treatment plan for managing autoimmune conditions and improving quality of life.

Citations

This content was written by AI and reviewed by a human for quality and compliance.